DOCSLIB.ORG

Journal of Drugs in Dermatology EDITOR-IN-CHIEF Perry Robins MD CO-EDITOR-IN-CHIEF Deborah S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Journal of Drugs in Dermatology EDITOR-IN-CHIEF Perry Robins MD CO-EDITOR-IN-CHIEF Deborah S Contents | Zoom In | Zoom Out | Search Issue | Next Page ISSN: 1545 9616 July 2019 • Volume 18 • Issue 7 JDD SPECIAL FOCUS: SKIN OF Do Not Copy Penalties ApplyCOLOR Image credit page 618 CONTINUING EDUCATION: Patient-focused Treatments in Rosacea Management Knowledge Gaps in SOC Aesthetic Treatment A Survey-Based Comparison of Sun Safety Practices Review of Treatment for Impetigo Laser-Assisted Delivery of Treatment for Plantar Warts Topical Collagen Powder vs Primary Closure for Punch Biopsy Wounds RESIDENT ROUNDS NEWS, VIEWS, & REVIEWS PIPELINE PREVIEWS CLINICAL TRIAL REVIEW ANTI-AGING · AESTHETIC · MEDICAL DERMATOLOGY c2 heliocare 1 page Previous Page | Contents | Zoom In | Zoom Out | Search Issue | Cover | Next Page Help your skin protect itself from the aging effects of free radicals.* All Heliocare products are made with exclusive Fernblock® Polypodium leucotomos extract (PLE) technology, are gluten-free, vegan and contain no artificial dyes. Heliocare’s Fernblock® technology was both developed and studied extensively by leading dermatologists. With over 75 publications and clinical studies covering safety, efficacy, and consistency, Heliocare is proud to be the market leader and the most heavily studied PLE supplement available. Heliocare 60ct 240 mg of Fernblock® Polypodium leucotomos extract (PLE) technology 60 Capsules c2 heliocareHeliocare Advanced NEW 120 Capsules (2 capsules per serving) 1 pageEachDo servingNot Copy of Heliocare Advanced contains: PenaltiesNon-flushing Apply form of Nicotinamide (Vitamin B3) 500 mg 240 mg of Fernblock® Polypodium leucotomos extract (PLE) technology Heliocare Ultra 480 mg of Fernblock® Polypodium leucotomos extract (PLE) technology Additional antioxidant benefit with pomegranate extract & L-ascorbic acid 36 Capsules Available exclusively at Dermatology offices * This statements has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. DERMATOLOGIST RECOMMENDED Previous Page | Contents | Zoom In | Zoom Out | Search Issue | Cover | Next Page July 2019 595 Volume 18 • Issue 7 Copyright © 2019 EDITORIAL BOARD Journal of Drugs in Dermatology EDITOR-IN-CHIEF Perry Robins MD CO-EDITOR-IN-CHIEF Deborah S. Sarnoff MD SENIOR EDITORS Macrene Alexiades MD PhD Dee Anna Glaser MD Ronald L. Moy MD Gerhard Sattler MD Robert Baran MD C. William Hanke MD Keyvan Nouri MD James M. Spencer MD Joseph B. Bikowski MD William Levis MD Neil S. Sadick MD Susan H. Weinkle MD SENIOR ASSOCIATE ASSOCIATE EDITORS Neil Alan Fenske MD Cleire Paniago-Pereira MD EDITORS Dale M. Abadir MD Rebecca Fitzgerald MD Anna C. Pavlick MD Kenneth Beer MD William Abramovits MD Alina A. Fratila MD Christopher R. Payne MD Martin Braun MD Andrew F. Alexis MD MPH Alejandro Camps Fresnada MD António Picoto MD Jeffrey Phillip Callen MD Shawn Allen MD Ellen C. Gendler MD Sheldon V. Pollack MD Jean Carruthers MD Rex A. Amonette MD Dore Gilbert MD Babar K. Rao MD James Q. Del Rosso DO Robert Anolik MD David J. Goldberg MD Wendy E. Roberts MD Lawrence F. Eichenfield MD Martha P. Arroyo MD Leonard H. Goldberg MD Amy E. Rose MD Patricia Farris MD Robin Ashinoff MD Robert H. Gotkin MD Steven Rosenberg MD Norman Goldstein MD Marc R. Avram MD Gloria F. Graham MD Lidia Rudnicka MD Aditya K. Gupta MD PhD David E. Bank MD John Hawk MD Bijan Safai MD Elizabeth Hale MD Jay G. Barnett MD Michael P. Heffernan MD Eli R. Saleeby MD Sherry H. Hsiung MD Eliot F. Battle Jr. MD William L. Heimer II MD Fitzgeraldo A. Sanchez-Negron MD Leon Kircik MD Richard G. Bennett MD N. Patrick Hennessey MD Miguel Sanchez-Viera MD Mark Lebwohl MD Diane S. Berson MD Alysa R. Herman MD Julie Schaffer MD Henry W. Lim MD Ronald R. Branacaccio MD George J. Hruza MD Bryan C. Schultz MD Flor Mayoral MD Rana Anadolu Brasie MD Shasa Hu MD Daniel Mark Siegel MD Maurizio Podda MD PhD Jeremy A. Brauer MD Mark J. Jaffe MD Arthur J. Sober MD Jeffrey Orringer MD Gary Brauner MD Do NotJared Copy Jagdeo MD Nicholas A. Soter MD Maritza Perez MD Neil Brody MD PhD PenaltiesS. BrianApply Jiang MD Jennifer Stein MD Kevin Pinski MD Lance H. Brown MD Bruce E. Katz MD Fernando Stengel MD Luigi Rusciani Scorza MD Isaac Brownell MD PhD Mark D. Kaufmann MD Hema Sundaram MD Ritu Saini MD Karen E. Burke MD PhD Amor Khachemoune MD Susan C. Taylor MD Jerome l. Shupack MD Mariano Busso MD Poong Myung Kim MD Emily Tierney MD Amy Taub MD Francisco M. Camacho-Martinez MD Christine Ko MD George-Sorin Tiplica MD PhD Danny Vleggaar MD Marian Cantisano-Zilkha MD David Kriegel MD Ella L. Toombs MD Brian Zelickson MD Alastair Carruthers MD Pearon G. Lang MD Irene J. Vergilis-Kalner MD Roger I. Ceilley MD Aimee Leonard MD Steven Wang MD Clay J. Cockerell MD Mary P. Lupo MD Ken Washenik MD PhD David E. Cohen MD Alan Matarasso MD Jeffrey Weinberg MD Julian S. Conejo-Mir MD Alan Menter MD Robert A. Weiss MD Elizabeth Alvarez Connelly MD Warwick L. Morison MD W. Phillip Werschler MD FEATURE EDITORS Ira Davis MD Rhoda S. Narins MD Ronald G. Wheeland MD Kendra G. Bergstrom MD Calvin Day MD Mark Naylor MD Jai Il Youn MD Joel L. Cohen MD Doris Day MD Kishwer S. Nehal MD John Zic MD Adam Friedman MD Jeffrey S. Dover MD Martino Neumann MD John A. Zitelli MD James L. Griffith MD Zoe Diana Draelos MD Nelson Lee Novick MD Marissa Heller MD Madeleine D. Duvic MD Jorge J. Ocampo Candiani MD Isaac Zilinsky MD Mohamed L. Elsaie MD Philip Orbuch MD Joseph C. English III MD Ariel Ostad MD PAST CO-EDITORS-IN-CHIEF Elizabeth Hale MD (2004) Impact Factor Susan H. Weinkle MD (2005-2008) Impact Factor Score: 1.527* ® * Keyvan Nouri MD (2005-2008) Normalized Eigenfactor Score: 0.660 Article Influence Score: 0.409* Sherry H. Hsiung MD (2008) *Clarivate Analytics, Formerly the IP & Science Business of James M. Spencer MD (2009-2013) Thomson Reuters, June 2018 Previous Page | Contents | Zoom In | Zoom Out | Search Issue | Cover | Next Page July 2019 596 Volume 18 • Issue 7 Copyright © 2019 TABLE OF CONTENTS Journal of Drugs in Dermatology CONTINUING EDUCATION ARTICLE 606 Patient-focused Solutions in Rosacea Management: Treatment Challenges in Special Patient Groups Ahuva Cices MD, Andrew F. Alexis MD MPH GUEST EDITORIAL 615 Global Perspectives of the Patient of Color Cheryl M. Burgess MD FAAD ORIGINAL ARTICLES Do Not Copy 616 Myths and Knowledge Gaps in the Aesthetic Treatment of Patients With Skin of Color Penalties Apply Andrew F. Alexis MD MPH, Julius Few MD, Valerie D. Callender MD, Pearl Grimes MD, Jeanine Downie MD MA, Charles Boyd MD, Conor J. Gallagher PhD 623 Understanding the Female Hispanic and Latino American Facial Aesthetic Patient Sabrina Fabi MD, José Raúl Montes MD FACS FACCS, Shino Bay Aguilera DO, Vivian Bucay MD FAAD, Stephanie Manson Brown MBBS MRCS MFPM, Nazanin Ashourian PhD 633 Understanding the Female Asian American Facial Aesthetic Patient Annie Chiu MD, Kavita Mariwalla MD, Andrea Hui-Austin MD, Vic Narurkar MD, Carola de la Guardia PhD 642 In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream Pearl E. Grimes MD, David H. McDaniel MD, Mitchell Wortzman PhD, Diane Nelson RN MPH 649 A Survey-Based Comparison of Sun Safety Practices in a Representative Cohort of the General Public Versus Attendees of a Skin Cancer Screening Emily C. Murphy BS, Stephanie Kao BA, Huan Wang MS, Dechang Chen PhD, Hong Nguyen MD MPH, Adam J. Friedman MD Previous Page | Contents | Zoom In | Zoom Out | Search Issue | Cover | Next Page ™ Do Not Copy Penalties Apply 12 Kamedis Eczema 8 10.9 Therapy Cream Kamedis Eczema Therapy Cream Vehicle 9.61 7 Vehicle 10 6.79 8.87 Comparator Comparator 8.27 6 8.48 5.5 8 7.16 7.06 5 4.72 4.7 6 4 6.19 BSA (%) (%) BSA 3.79 4.12 5.26 3 4 3.78 1.89 3.38 BSA Improvement (%) Improvement BSA 2 2 1.37 1 1.29 0.21 0 0 0 1 2 3 4 0 1 2 3 4 Duration (Weeks #) Duration (Weeks #) KAMEDIS_AD_JDD_061319_V3_RELEASE_OL.indd 1 7/1/19 4:04 PM Previous Page | Contents | Zoom In | Zoom Out | Search Issue | Cover | Next Page July 2019 598 Volume 18 • Issue 7 Copyright © 2019 TABLE OF CONTENTS Journal of Drugs in Dermatology ORIGINAL ARTICLES (CONTD) 655 Topical Ozenoxacin Cream 1% for Impetigo: A Review Lawrence Schachner MD FAAD, Anneke Andriessen PhD, Neal Bhatia MD, Ayman Grada MD MS, Dillon Patele 663 Laser-Assisted Delivery of Topical Cidofovir in the Treatment of Plantar Warts Margaret Coates BA, Jigar Patel MD, Courtney Powers PA-C, Claude Burton MD 667 A Head-to-Head Comparison of Topical Collagen Powder to Primary Closure for Acute Full-Thickness Punch Biopsy-Induced Human Wounds: An Internally Controlled Pilot Study Azam Qureshi BA, Emily Murphy BS, Rose Milando BA, Monica Rengifo-Pardo MD, Courtney Clayton, Adam Friedman MD FAAD 675 Non-Submental Applications of Injectable Deoxycholic Acid: A Systematic Review Calvin T. Sung MD, Alfred Lee BA, Franchesca Choi BS RPh, Margit Juhasz MD, Natasha Atanaskova Mesinkovska MD PhD 682 Effective and Safe RepeatedDo Full-Face Not TreatmentsCopy With AbobotulinumtoxinA, Hyaluronic Acid Filler, and PenaltiesSkin Boosting Apply Hyaluronic Acid Per Hedén MD, Doris Hexsel MD, Hugues Cartier MD, Per Bergentz MD, Henry Delmar MD, Fernanda Camozzato MD, Carolina Siega BSc, Cecilia Skoglund PhD, Carolina Edwartz PhD, Maria Norberg PhD, Philippe Kestemont MD CASE REPORTS 690 An Atypical Presentation of PLEVA: Case Report and Review of the Literature Constance Ediale MS, Kayla Felix MS, Kathryn Anderson MD, Christine Ahn MD, Amy J.
Load more

Recommended publications
  • Basal Cell Carcinoma: Topical Therapy Versus Surgical Treatment
    Journal of the Saudi Society of Dermatology & Dermatologic Surgery (2012) 16,41–51 King Saud University Journal of the Saudi Society of Dermatology & Dermatologic Surgery www.ksu.edu.sa www.jssdds.org www.sciencedirect.com REVIEW ARTICLE Basal cell carcinoma: Topical therapy versus surgical treatment Khalifa E. Sharquie a,*, Adil A. Noaimi b,1 a Scientific Council of Dermatology and Venereology, Iraqi Board for Medical Specializations, Iraq b Department of Dermatology and Venereology, College of Medicine, University of Baghdad, Iraq Received 1 November 2011; revised 7 June 2012; accepted 7 June 2012 Available online 6 July 2012 KEYWORDS Abstract Basal cell carcinoma (BCC) is a non-melanoma skin cancer and is one of the commonest Basal cell carcinoma; malignancies of the skin encountered in daily clinical practice. It derives from non-keratinizing cells Topical therapy of BCC by that originate in the basal layer of the epidermis. It accounts for approximately 75% of all skin can- podophylline; cer in the world, and 53.2% in Iraqi patients. Generally, most BCC cases are sporadic, but it may Surgical treatment also appear in genetic disorders such as Gorlin’s syndrome, Rombo’s syndrome, and xeroderma pigmentosa (XP). If left untreated, BCC will continue to invade locally and may result in substantial tissue damage that compromises function and cosmetic look. Metastasis is an extremely rare event. The tumor characteristically develops on sun-exposed skin of lighter-skinned individuals. There are two main modalities of therapy including topical like: Imiquimod, 5-fluorouracil (5- FU), photodynamic therapy (PDT), radiation therapy (RT), topical & intralesional zinc sulfate and topical 25% podophylline.
    [Show full text]
  • Milia: a Review and Classification
    15 March 2005 Use of Articles in the Pachyonychia Congenita Bibliography The articles in the PC Bibliography may be restricted by copyright laws. These have been made available to you by PC Project for the exclusive use in teaching, scholar- ship or research regarding Pachyonychia Congenita. To the best of our understanding, in supplying this material to you we have followed the guidelines of Sec 107 regarding fair use of copyright materials. That section reads as follows: Sec. 107. - Limitations on exclusive rights: Fair use Notwithstanding the provisions of sections 106 and 106A, the fair use of a copyrighted work, including such use by reproduction in copies or phonorecords or by any other means specified by that section, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright. In determining whether the use made of a work in any particular case is a fair use the factors to be considered shall include - (1) the purpose and character of the use, including whether such use is of a commercial nature or is for nonprofit educational purposes; (2) the nature of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole; and (4) the effect of the use upon the potential market for or value of the copyrighted work. The fact that a work is unpublished shall not itself bar a finding of fair use if such finding is made upon consideration of all the above factors.
    [Show full text]
  • Milia: a Review and Classification
    Milia: A review and classification David R. Berk, MD, and Susan J. Bayliss, MD Saint Louis, Missouri Milia are frequently encountered as a primary or secondary patient concern in pediatric and adult clinics, and in general or surgical dermatology practice. Nevertheless, there are few studies on the origin of milia and, to our knowledge, there is no previous comprehensive review of the subject. We review the various forms of milia, highlighting rare variants including genodermatosis-associated milia, and present an updated classification. ( J Am Acad Dermatol 2008;59:1050-63.) ilia (singular: milium) are small (generally # 3 mm) white, benign, superficial kerat- Abbreviations used: inous cysts. Histologically, they resemble APL: atrichia with papular lesions M BCNS: Basal cell nevus syndrome miniature infundibular cysts, containing walls of BDCS: Bazex-Dupre-Christol syndrome stratified squamous epithelium several layers thick BFH: basaloid follicular hamartoma with a granular cell layer (Fig 1). Although benign CK: cytokeratin EB: epidermolysis bullosa primary milia are commonly encountered in clinical EBS: epidermolysis bullosa simplex practice, milia also occur in a variety of other condi- EVHC: eruptive vellus hair cyst tions, many of which are rare. They may arise either GBFHS: generalized basaloid follicular hamartoma syndrome spontaneously (primary milia) or secondary to var- MEM: multiple eruptive milia ious processes (secondary milia), as few or many MEP: milia en plaque lesions, and isolated or associated with other clinical MUS: Marie-Unna hypotrichosis 1 OFDS: orofaciodigital syndrome findings. Hubler et al proposed dividing milia into OMIM: Online Mendelian Inheritance in Man primary, secondary, and ‘‘other’’ types, a classifica- PC: pachyonychia congenita tion that Wolfe and Gurevitch2 modified.
    [Show full text]
  • Download Download
    INTERNATIONAL JOURNAL FOR INNOVATION EDUCATION AND RESEARCH ONLINE ISSN: 2411-2933 PRINT - ISSN: 2411-3123 INTERNATIONAL EDUCATIVE RESEARCH FOUNDATION AND PUBLISHER (IERFP) Volume- 8 Number- 3 March Edition International Journal for Innovation Education and Research www.ijier.net Vol:-8 No-3, 2020 About the Journal Name: International Journal for Innovation Education and Research Publisher: Shubash Biswas International Journal for Innovation Education and Research 44/1 Kallyanpur Main road Mirpur, Dhaka 1207 Bangladesh. Tel: +8801827488077 Copyright: The journal or any part thereof may be reproduced for academic and research purposes with an appropriate acknowledgment and a copy of the publication sent to the editor. Written permission of the editor is required when the intended reproduction is for commercial purposes. All opinions, information’s and data published in the articles are an overall responsibility to the author(s). The editorial board does not accept any responsibility for the views expressed in the paper. Edition: March 2020 Publication fee: $100 and overseas. International Educative Research Foundation and Publisher ©2020 Online-ISSN 2411-2933, Print-ISSN 2411-3123 March 2020 Editorial Dear authors, reviewers, and readers It has been a month since I was given the privilege to serve as the Chief Editor of the International Journal for Innovation Education and Research (IJIER). It is a great pleasure for me to shoulder this duty and to welcome you to THE VOL-8, ISSUE-3 of IJIER which is scheduled to be published on 01st March 2020. International Journal for Innovation Education and Research (IJIER) is an open access, peer-reviewed and refereed multidisciplinary journal which is published by the International Educative Research Foundation and Publisher (IERFP).
    [Show full text]
  • Epidemiology of Basal Cell Carcinoma *
    292 REVISÃO L Epidemiologia do carcinoma basocelular * Epidemiology of basal cell carcinoma Valquiria Pessoa Chinem1 Hélio Amante Miot2 Resumo: O carcinoma basocelular é a neoplasia maligna mais comum em humanos e sua incidência vem aumentando nas últimas décadas. Sua grande frequência gera significativo ônus ao sistema de saúde, configurando problema de saúde pública. Apesar das baixas taxas de mortalidade e de rara ocor- rência de metástases, o tumor pode apresentar comportamento invasivo local e recidivas após o trata- mento, provocando importante morbidade. Exposição à radiação ultravioleta representa o principal fator de risco ambiental associado a sua gênese. Entretanto, descrevem-se outros elementos de risco: fotótipos claros, idade avançada, história familiar de carcinomas de pele, olhos e cabelos claros, sardas na infância e imunossupressão, além de aspectos comportamentais, como exercício profissional expos- to ao sol, atividade rural e queimaduras solares na juventude. Entre 30% e 75% dos casos esporádicos estão associados à mutação do gene patched hedgehog, mas outras alterações genéticas são ainda descritas. A neoplasia é comumente encontrada concomitantemente com lesões cutâneas relacionadas à exposição solar crônica, tais como: queratoses actínicas, lentigos solares e telangiectasias faciais. A pre- venção do carcinoma basocelular se baseia no conhecimento de fatores de risco, no diagnóstico e trata- mento precoces e na adoção de medidas específicas, principalmente, nas populações susceptíveis. Os autores apresentam uma revisão da epidemiologia do carcinoma basocelular. Palavras-chave: Injeções intradérmicas; Pele; Revisão; Terapêutica Abstract: Basal cell carcinoma is the most common malignant neoplasm in humans and its incidence has increased over the last decades. Its high frequency significantly burdens the health system, making the disease a public health issue.
    [Show full text]
  • List of Rare Diseases and Synonyms
    Marche des Maladies Rares – Alliance Maladies Rares DecemberJuly 2014 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 66634 3-methylglutaconic aciduria type 5 2975 46,XX disorder of sex development - skeletal anomalies 79154 2-aminoadipic 2-oxoadipic aciduria 352328 3-methylglutaconic aciduria with deafness - encephalopathy - Leigh-like syndrome 243 46,XX gonadal dysgenesis 19 2-hydroxyglutaric acidemia 67046 3-methylglutaconyl-CoA hydratase 243 46,XX ovarian dysgenesis 19 2-hydroxyglutaric aciduria deficiency 2138 46,XX ovotesticular disorder of sex 391417 2-methyl-3-hydroxybutyric aciduria 67046 3MG-CoA hydratase deficiency development 391428 2-methyl-3-hydroxybutyric aciduria, 79351 3-phosphoglycerate dehydrogenase 2138 46,XX ovotesticular DSD classic type deficiency 243 46,XX pure gonadal dysgenesis 391428 2-methyl-3-hydroxybutyric aciduria, 79350 3-phosphoserine phosphatase deficiency infantile type 393 46,XX testicular disorder of sex 869 4A syndrome development 391457 2-methyl-3-hydroxybutyric aciduria, neonatal type 2118 4-alpha-hydroxyphenylpyruvate 393 46,XX testicular DSD hydroxylase deficiency 391417 2-methyl-3-hydroxybutyryl-CoA 199310 46,XX/46,XY chimerism dehydrogenase deficiency 88637 4H syndrome 242 46,XY CGD 391428 2-methyl-3-hydroxybutyryl-CoA 2118 4-HPPD deficiency 242 46,XY complete gonadal dysgenesis dehydrogenase deficiency,
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Orphanet Report Series Rare Diseases collection DecemberDecember 2012 2009Number 1 List of rare diseases Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 284169 10p11.21p12.31 microdeletion syndrome 1727 22q11.2 microduplication syndrome 2975 46,XX disorder of sex development - skeletal anomalies 276413 10q22.3q23.3 microdeletion syndrome 79154 2-aminoadipic aciduria 98081 46,XX disorder of sex development 276422 10q22.3q23.3 microduplication syndrome 19 2-hydroxyglutaric aciduria due to synthetic oral progestagen or 300305 11p15.4 microduplication syndrome 79157 2-methylbutyryl-CoA dehydrogenase diethylstilbestrol deficiency 94063 12q14 microdeletion syndrome 98080 46,XX disorder of sex development due to 261349 2p15p16.1 microdeletion syndrome 289513 12q15q21.1 microdeletion syndrome testosterone or related steroids 163693 2p21 microdeletion syndrome 261120 14q11.2 microdeletion syndrome 243 46,XX gonadal dysgenesis 228402 2q23.1 microdeletion syndrome 261229 14q11.2 microduplication syndrome 98779 46,XX iatrogenic androgen-induced disorder 1617 2q24 microdeletion syndrome of sex development of maternal origin 261144 14q12 microdeletion syndrome 251014 2q31.1 microdeletion syndrome 393 46,XX testicular disorder of sex development 264200 14q22q23 microdeletion syndrome 294026 2q31.1 microduplication syndrome 242 46,XY complete gonadal dysgenesis 261183 15q11.2 microdeletion syndrome 251019 2q32q33 microdeletion
    [Show full text]